Correlation Between Lumos Pharma and Avalo Therapeutics

Can any of the company-specific risk be diversified away by investing in both Lumos Pharma and Avalo Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lumos Pharma and Avalo Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lumos Pharma and Avalo Therapeutics, you can compare the effects of market volatilities on Lumos Pharma and Avalo Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lumos Pharma with a short position of Avalo Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lumos Pharma and Avalo Therapeutics.

Diversification Opportunities for Lumos Pharma and Avalo Therapeutics

0.55

Correlation Coefficient

Lumos Pharma  Avalo Therapeutics

Very weak diversification

The 3 months correlation between Lumos and Avalo is 0.55. Overlapping area represents the amount of risk that can be diversified away by holding Lumos Pharma and Avalo Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Avalo Therapeutics and Lumos Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lumos Pharma are associated (or correlated) with Avalo Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Avalo Therapeutics has no effect on the direction of Lumos Pharma i.e., Lumos Pharma and Avalo Therapeutics go up and down completely randomly.

Pair Corralation between Lumos Pharma and Avalo Therapeutics

Given the investment horizon of 90 days Lumos Pharma is expected to generate 0.62 times more return on investment than Avalo Therapeutics. However, Lumos Pharma is 1.61 times less risky than Avalo Therapeutics. It trades about 0.07 of its potential returns per unit of risk. Avalo Therapeutics is currently generating about 0.05 per unit of risk. If you would invest  387.00  in Lumos Pharma on September 15, 2024 and sell it today you would earn a total of  47.00  from holding Lumos Pharma or generate 12.14% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	98.44%
Values	Daily Returns

Lumos Pharma  vs.  Avalo Therapeutics

Lumos Pharma

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Lumos Pharma are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent primary indicators, Lumos Pharma displayed solid returns over the last few months and may actually be approaching a breakup point.

Avalo Therapeutics

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Avalo Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Avalo Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Lumos Pharma and Avalo Therapeutics

The main advantage of trading using opposite Lumos Pharma and Avalo Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lumos Pharma position performs unexpectedly, Avalo Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Avalo Therapeutics will offset losses from the drop in Avalo Therapeutics' long position.

The idea behind Lumos Pharma and Avalo Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.